Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Interest Income

Income earned on cash, deposits, and investments held by the company.

Valneva SENASDAQ: VALN

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income growth accelerates

Q1 FY2026 interest income of €526K rose 2.9% year over year, ahead of the -27.6% change in trailing-twelve-month interest income. Over 3 fiscal years it compounded at +90.7% a year.

Context

  • Interest income amounted to 1.0% of revenue in FY2025, down 0.4 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +2.9% holds above the trailing-twelve-month pace of -27.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€526K— QoQ
Last fiscal yearDec 2025
€1.8M-23.7% YoY
LTMMar 2026
€1.89M-27.6% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.9%——
1 year-23.7%——
3-year CAGR+90.7%——
5-year CAGR——
10-year CAGR——

Interest Income history

EUR · from the income statement

Latest · FY2025
1.8M EUR
Year-over-year change
-23.7%
4-year CAGR
+64.0%

Interest Income vs competitors

How VALN compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -27.6% is the 5th highest of 7, against a peer median of -17.5%.
  • Interest income amounts to 1.2% of revenue for VALN, versus a peer median of 10.7%.
VALN Competitors
Interest Income for VALN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$553.61M USD+13486.2%-20.3%—
MRNAModerna, Inc.LTM Sep 2026$271M USD-19.1%+16.2%10.7%
PCVXVaxcyte, Inc.LTM Jun 2026$108.08M USD-15.9%+142.9%—
VIRVir Biotechnology, Inc.LTM Mar 2026$35.14M USD-44.1%+12.7%53.7%
IBRXImmunityBio, Inc.LTM Sep 2026$11.91M USD+183.5%+35.2%6.5%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$9.27M USD-47.9%+57.6%20.4%
VALNValneva SELTM Mar 2026€1.89M EUR-27.6%+90.7%1.2%
NVAXNovavax, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding VALN) —-17.5%+25.7%10.7%

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue348.09M361.3M153.71M169.58M174.66M
Cost of Revenue187.92M324.44M100.88M98.54M107.14M
Gross Profit160.17M36.86M52.84M71.04M67.52M
Gross Margin46.0%10.2%34.4%41.9%38.7%
Research & Development173.28M104.92M59.89M74.14M85.3M
Selling, General & Admin71.25M57.58M96.55M95.11M74.68M
Operating Expenses221.56M150.31M134.92M57.71M149.15M
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
EBITDA(38.74M)(104.73M)(57.72M)32.08M(50.47M)
EBITDA Margin-11.1%-29.0%-37.6%18.9%-28.9%
Operating Income(61.39M)(113.44M)(82.09M)13.33M(81.63M)
Operating Margin-17.6%-31.4%-53.4%7.9%-46.7%
Interest Income249K260K1.21M2.36M1.8M
Interest Expense16.96M19.05M23.33M23.98M41.9M
Other Income / Expenses(8.59M)(31.37M)(16.54M)(24.82M)(32.49M)
Income Before Tax(69.98M)(144.82M)(98.63M)(11.49M)(114.12M)
Pre-Tax Margin-20.1%-40.1%-64.2%-6.8%-65.3%
Income Tax Expense3.45M(1.54M)2.8M761K1.07M
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Net Margin-21.1%-39.7%-66.0%-7.2%-66.0%
EPS (Basic)(1.50)(2.48)(1.46)(0.17)(1.32)
EPS (Diluted)(1.50)(2.48)(1.46)(0.17)(1.32)
Weighted Avg Shares48.81M57.74M69.47M70.26M84.09M
Weighted Avg Shares (Diluted)48.81M57.74M69.31M70.26M84.09M

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.